AZN's Tagrisso Gets Approval in the EU for Expanded Use in NSCLC

Zacks2024-12-23

AstraZeneca AZN announced that its blockbuster cancer drug, Tagrisso (osimertinib), has been approved in the EU for expanded use in non-small cell lung cancer (NSCLC). The eligible patient population ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2493934307?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/spvq99_pwlnf7s60ZXBlKg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/06708d71c63051ca48bf1855727f077b","is_english":true,"pubTime":"2024-12-23 23:56","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2493934307","market":"us","top_or_hot":-1,"title":"AZN's Tagrisso Gets Approval in the EU for Expanded Use in NSCLC","media":"Zacks","content":"<div>\n<p>AstraZeneca AZN announced that its blockbuster cancer drug, Tagrisso (osimertinib), has been approved in the EU for expanded use in non-small cell lung cancer (NSCLC).\nThe eligible patient population ...</p>\n\n<a href=\"https://finance.yahoo.com/news/azns-tagrisso-gets-approval-eu-155600638.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AZN's Tagrisso Gets Approval in the EU for Expanded Use in NSCLC</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAZN's Tagrisso Gets Approval in the EU for Expanded Use in NSCLC\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-23 23:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/azns-tagrisso-gets-approval-eu-155600638.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AstraZeneca AZN announced that its blockbuster cancer drug, Tagrisso (osimertinib), has been approved in the EU for expanded use in non-small cell lung cancer (NSCLC).\nThe eligible patient population ...</p>\n\n<a href=\"https://finance.yahoo.com/news/azns-tagrisso-gets-approval-eu-155600638.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://finance.yahoo.com/news/azns-tagrisso-gets-approval-eu-155600638.html","article_id":"2493934307","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/spvq99_pwlnf7s60ZXBlKg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/06708d71c63051ca48bf1855727f077b"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2493934307","pubTimestamp":1734969360,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"AstraZenecaAZN announced that its blockbuster cancer drug, Tagrisso , has been approved in the EU for expanded use in non-small cell lung cancer .The eligible patient population includes adults with locally advanced, unresectable NSCLC with EGFR exon 19 deletions  or exon 21  substitution mutations whose disease has not progressed during or following platinum-based chemoradiation therapy. The FDAapprovedthis combinationin September for a similar indication.The nod in the EU is based on data from the phase III LAURAstudy, which showed that treatment with Tagrisso reduced the risk of disease progression or death by 84% compared to placebo. Patients treated with the drug experienced a median progression-free survival of 39.1 months compared with 5.6 months for patients in the placebo group. The drugs’ safety and tolerability profiles were consistent with prior studies and no new safety concerns were identified.Last month, the EMA’s advisory committee adopted a positive opinion, recommendi","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4139":"生物科技","SPRO":"Spero Therapeutics Inc.","BK4007":"制药","BK4196":"保健护理服务","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","CTMX":"CytomX","AZN":"阿斯利康","BK4588":"碎股","BK4568":"美国抗疫概念","CSTL":"Castle Biosciences, Inc.","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","BK4156":"煤与消费用燃料","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU1829250122.USD":"高盛欧洲核心股票组合Acc"},"translate_title":"AZN的Tagrisso在欧盟获得批准扩大用于非小细胞肺癌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CTMX":1,"SPRO":1,"AZN":1,"CSTL":1},"content_text":"AstraZeneca AZN announced that its blockbuster cancer drug, Tagrisso (osimertinib), has been approved in the EU for expanded use in non-small cell lung cancer (NSCLC).\nThe eligible patient population includes adults with locally advanced, unresectable NSCLC with EGFR exon 19 deletions (ex19del) or exon 21 (L858R) substitution mutations whose disease has not progressed during or following platinum-based chemoradiation therapy. The FDA approved this combination in September for a similar indication.\nThe nod in the EU is based on data from the phase III LAURA study, which showed that treatment with Tagrisso reduced the risk of disease progression or death by 84% compared to placebo. Patients treated with the drug experienced a median progression-free survival of 39.1 months compared with 5.6 months for patients in the placebo group. The drugs’ safety and tolerability profiles were consistent with prior studies and no new safety concerns were identified.\nLast month, the EMA’s advisory committee adopted a positive opinion, recommending the label expansion of AstraZeneca’s Tagrisso for the NSCLC indication. In the past three months, AstraZeneca’s shares have lost 15% compared with the industry’s 17.4% decline.\nImage Source: Zacks Investment Research\nTagrisso is currently approved in the EU for four indications, all across different settings in the NSCLC indication. The drug is considered the current standard of care for EGFR-mutated NSCLC in the first-line setting.\nPer AstraZeneca, more than 450,000 people in the EU are diagnosed with lung cancer annually. Of these, 80-85% have NSCLC, and 10-15% of NSCLC cases involve tumors with an EGFR mutation. Tagrisso's EU approval for the new NSCLC indication is its fifth major approval based on the LAURA study, following approvals in the United States, Switzerland, South Korea and Australia, with reviews ongoing in China, Japan and other countries.\nTagrisso - A Key Top-Line Driver for AZN\nTagrisso is approved in more than 100 countries worldwide, including the United States, the EU and Japan, for use in different NSCLC settings. In the first nine months of 2024, the drug added sales worth $4.9 billion to AstraZeneca’s top line, up 15% year over year. Sales of this drug have been rising, driven by strong demand as a first-line and adjuvant treatment.\nAstraZeneca is also evaluating the drug in multiple-label expansion studies in lung cancer indications. This includes two late-stage studies, one evaluating the drug in the neoadjuvant setting and another in the early-stage adjuvant resectable setting. Continued label expansion for Tagrisso into additional indications and patient populations should boost drug sales in the future.\n\nAstraZeneca PLC Price and Consensus\n\nAstraZeneca PLC price-consensus-chart | AstraZeneca PLC Quote\n\nAZN’s Zacks Rank & Stocks to Consider\nAstraZeneca currently carries a Zacks Rank #3 (Hold).\nSome better-ranked stocks from the sector are Castle Biosciences CSTL, CytomX Therapeutics CTMX and Spero Therapeutics SPRO, each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.\nIn the past 60 days, 2024 estimates for Castle Biosciences have improved from a loss of 59 cents per share to earnings of 34 cents. During the same timeframe, loss per share estimates for 2025 have narrowed from $2.15 to $1.84. In the past three months, shares of Castle Biosciences have lost 5.9%.\nCSTL’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 172.72%.\nIn the past 60 days, estimates for CytomX Therapeutics’ 2024 loss per share have narrowed from 29 cents to 5 cents. Estimates for 2025 loss per share have narrowed from 56 cents to 35 cents during the same timeframe. In the past three months, CTMX stock has lost 8.4%.\nCytomX’s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average surprise of 115.70%.\nIn the past 60 days, estimates for Spero Therapeutics’ 2024 loss per share have narrowed from $1.59 to $1.29. Estimates for 2025 loss per share have narrowed from $1.54 to 79 cents during the same timeframe. In the past three months, Spero’s shares have lost 25.4%.\nSPRO’s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average surprise of 94.42%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nAstraZeneca PLC (AZN) : Free Stock Analysis Report\nCytomX Therapeutics, Inc. (CTMX) : Free Stock Analysis Report\nSpero Therapeutics, Inc. (SPRO) : Free Stock Analysis Report\nCastle Biosciences, Inc. (CSTL) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2493934307"}